Amylin, Lilly Enter Supply Deal for Diabetes Drug Exenatide
By Catherine Hollingsworth
Thursday, October 23, 2008
Despite a modest decrease in Byetta (exenatide) sales, Amylin Pharmaceuticals Inc. said it ended that quarter with strong revenues overall and soon will get a $125 million boost from a deal to supply partner Eli Lilly and Co. with a once-weekly version of the drug, upon approval. (BioWorld Today)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.